Mechanisms of hormonal prevention of breast cancer

被引:41
|
作者
Medina, D [1 ]
Sivaraman, L
Hilsenbeck, SG
Conneely, O
Ginger, M
Rosen, J
O'Malley, BW
机构
[1] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA
[2] Baylor Coll Med, Breast Ctr, Dept Med, Houston, TX 77030 USA
来源
CANCER PREVENTION: MOLECULAR MECHANISMS TO CLINICAL APPLICATIONS | 2001年 / 952卷
关键词
rat; mammary gland; estrogen; progesterone; estrogen receptor; cell proliferation; p53; gene expression; subtractive hybridization;
D O I
10.1111/j.1749-6632.2001.tb02725.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Reproductive history is a consistent risk factor for human breast cancer. Epidemiological studies have repeatedly demonstrated that early age of first pregnancy is a strong protective factor against breast cancer and provides a physiologically operative model to achieve a practical mode of prevention. In rodents, the effects of full-term pregnancy can be mimicked by a three-week exposure to low doses of estrogen and progesterone. Neither hormone alone is sufficient to induce protection. The cellular and molecular mechanisms that underlie hormone-induced refractoriness are largely unresolved. Our recent studies have demonstrated that an early cellular response that is altered in hormone-treated mammary cells is the initial proliferative burst induced by the chemical carcinogen methylnitrosourea. The decrease in proliferation is also accompanied by a decrease in the ability of estrogen receptor-positive cells to proliferate. RNA expression of several mammary cell-cycle-related genes is not altered in hormone-treated mice; however, immunohistochemical assays demonstrate that the protein level and nuclear compartmentalization of the p53 tumor suppressor gene are markedly upregulated as a consequence of hormone treatment. These results support the hypothesis that hormone stimulation, at a critical period in mammary development, results in cells with persistent changes in the intracellular regulatory loops governing proliferation and response to DNA damage. A corollary to this hypothesis is that the genes affected by estrogen and progesterone are independent of alveolar differentiation-specific genes. Suppressive subtractive hybridization-PCR methods have identified several genes that are differentially expressed as a consequence of prior estrogen and progesterone treatment. Future experiments are aimed at determining the mechanisms of hormone-induced upregulation of p53 protein expression as part of the overall goal of identifying and functionally characterizing the genes responsible for the refractory phenotype.
引用
收藏
页码:23 / 35
页数:13
相关论文
共 50 条
  • [21] Hormonal therapy in breast cancer: A model disease for the personalization of cancer care
    Puhalla, Shannon
    Bhattacharya, Saveri
    Davidson, Nancy E.
    MOLECULAR ONCOLOGY, 2012, 6 (02) : 222 - 236
  • [22] Hormonal Contraception and Breast Cancer Risk
    White, Nicole D.
    AMERICAN JOURNAL OF LIFESTYLE MEDICINE, 2018, 12 (03) : 224 - 226
  • [23] Hormonal regulation of tumor suppressor proteins in breast cancer cells
    Moudgil, VK
    Dinda, S
    Khattree, N
    Jhanwar, S
    Alban, P
    Hurd, C
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2001, 76 (1-5): : 105 - 117
  • [24] Mechanistic Examination of Walnuts in Prevention of Breast Cancer
    Vanden Heuvel, John P.
    Belda, Benjamin J.
    Hannon, Dan B.
    Kris-Etherton, Penny M.
    Grieger, Jessica A.
    Zhang, Jun
    Thompson, Jerry T.
    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2012, 64 (07): : 1078 - 1086
  • [25] Royal jelly and its hormonal effects in breast cancer: a literature review
    Aavani, Farzaneh
    Rahimi, Roja
    Goleij, Pouya
    Rezaeizadeh, Hossein
    Bahramsoltani, Roodabeh
    DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 32 (02) : 745 - 760
  • [26] Nutritional factors, physical activity, and breast cancer by hormonal receptor status
    Rosato, Valentina
    Bertuccio, Paola
    Bosetti, Cristina
    Negri, Eva
    Edefonti, Valeria
    Ferraroni, Monica
    Decarli, Adriano
    Talamini, Renato
    Dal Maso, Luigino
    Falcini, Fabio
    Montella, Maurizio
    Franceschi, Silvia
    La Vecchia, Carlo
    BREAST, 2013, 22 (05): : 887 - 893
  • [27] The Impact of Hormonal Contraceptives on Breast Cancer Pathology
    Dorchak, Jesse A.
    Maria, Sifat
    Guarinoni, Joseph L.
    Duensing, Anette
    Somiari, Stella
    Cavanaugh, Jane
    Deyarmin, Brenda
    Hu, Hai
    Iida, Joji
    Shriver, Craig D.
    Witt-Enderby, Paula A.
    HORMONES & CANCER, 2018, 9 (04): : 240 - 253
  • [28] Breast cancer risk with postmenopausal hormonal treatment
    Collins, JA
    Blake, JM
    Crosignani, PG
    HUMAN REPRODUCTION UPDATE, 2005, 11 (06) : 545 - 560
  • [29] Hormonal Crosstalk Between Thyroid and Breast Cancer
    Halada, Stephen
    Casado-Medrano, Victoria
    Baran, Julia A.
    Lee, Joshua
    Chinmay, Poojita
    Bauer, Andrew J.
    Franco, Aime T.
    ENDOCRINOLOGY, 2022, 163 (07)
  • [30] Thyroid Diseases and Breast Cancer
    Baldini, Enke
    Lauro, Augusto
    Tripodi, Domenico
    Pironi, Daniele
    Amabile, Maria Ida
    Ferent, Iulia Catalina
    Lori, Eleonora
    Gagliardi, Federica
    Bellini, Maria Irene
    Forte, Flavio
    Pacini, Patrizia
    Cantisani, Vito
    D'Andrea, Vito
    Sorrenti, Salvatore
    Ulisse, Salvatore
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (02):